A scientific conclave on the Indian Pharmacopoeia 2026 brought together regulators, academia and industry stakeholders in Jammu to deliberate on strengthening drug quality, safety and efficacy standards in India.

Organised by the Indian Pharmacopoeia Commission in collaboration with the Council of Scientific and Industrial Research, the event was held at CSIR-Indian Institute of Integrative Medicine on April 17, 2026. The conclave focused on advancing pharmacopoeial standards in line with evolving scientific and regulatory requirements. 

Discussions during the event underscored the critical role of the Indian Pharmacopoeia in ensuring uniform standards for pharmaceuticals across the country. Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines, particularly in a rapidly evolving pharmaceutical landscape. 

Technical sessions at the conclave covered key updates in IP 2026, including the development and revision of monographs, strengthening impurity standards and adopting modern analytical techniques. Deliberations also addressed regulatory perspectives, standardisation of phytopharmaceuticals and enhancements in microbiological and blood-related standards, reflecting a comprehensive push to upgrade pharmaceutical quality systems. 

An interactive session enabled stakeholders to exchange views on implementation challenges, industry preparedness and the importance of aligning Indian standards with global benchmarks. Participants emphasised that closer collaboration between regulators, scientific institutions and industry will be critical to ensuring effective adoption of updated pharmacopoeial standards. 

The conclave reaffirmed the Indian Pharmacopoeia Commission's commitment to continuously upgrade standards through scientific advancements and stakeholder engagement, strengthening public health safeguards and reinforcing trust in the quality of medicines in India.